Product Information
LITHIUM CARBONATE ER 450 MG TB is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.2590 per EA under NDC 64980027801. Its NADAC has been published 439 times since May 9, 2018.
FDA first approved this application on Jun 5, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
450 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
64980027801
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LITHIUM CARBONATEApproval Type
Generic (ANDA)
FDA Application
ANDA205663FDA Approved
6/5/2017
TE Code
AB
On Market Since
3/1/2018
Pharmacological Classes
Price Statistics
The NADAC for LITHIUM CARBONATE ER 450 MG TB has been published 439 times since May 9, 2018, and over the history we have for it it has risen 16.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2590 per EA |
|---|---|
| All-time high | $0.2723 (Apr 16, 2025) |
| All-time low | $0.1550 (Jul 20, 2022) |
| 52-week high | $0.2590 |
| 52-week low | $0.2474 |
| Median price | $0.2194 |
| Average price | $0.2173 |
| Largest weekly change | -37.9% (Nov 20, 2024) |
| Weeks tracked | 439 |
| Tracking since | May 9, 2018 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Lithium Carbonate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Mood Stabilizer class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LITHIUM CARBONATE ER 450 MG TB?
The current National Average Drug Acquisition Cost (NADAC) for LITHIUM CARBONATE ER 450 MG TB, manufactured by Rising Pharma Holdings Inc., is $0.2590 per EA (NDC 64980027801), effective Sep 30, 2026.
How has the price of LITHIUM CARBONATE ER 450 MG TB changed over time?
Over the history we have for it, the NADAC for LITHIUM CARBONATE ER 450 MG TB has risen 16.1%. It has been tracked across 439 weekly CMS publications since May 9, 2018.
What are the highest and lowest recorded NADAC prices for LITHIUM CARBONATE ER 450 MG TB?
Since May 9, 2018, the NADAC for LITHIUM CARBONATE ER 450 MG TB has ranged from a low of $0.1550 (Jul 20, 2022) to a high of $0.2723 (Apr 16, 2025), with a median of $0.2194 per EA.
Are there cheaper alternatives to LITHIUM CARBONATE ER 450 MG TB?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LITHIUM CARBONATE ER 450 MG TB in a comparable dosage form, but none are currently priced below it.
Who manufactures LITHIUM CARBONATE ER 450 MG TB?
LITHIUM CARBONATE ER 450 MG TB (NDC 64980027801) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.